Concomitant Chemoradiotherapy in Pyriform Sinus Carcinoma

Authors:
  • TSThierry M. Schmitt
    Thierry M. Schmitt
  • ATAndrei P. Timoshenko
    Andrei P. Timoshenko
  • PSPierre-Gilles Simon
    Pierre-Gilles Simon
  • JCJoanne de Cornulier
    Joanne de Cornulier
  • MDMarc Durand
    Marc Durand
  • AGAline Guillot
    Aline Guillot

Abstract
SQUAMOUS CELL carcinoma of the hypopharynx has one of the worst prognoses of all upper aerodigestive tract cancers, particularly for tumors arising in the pyriform sinus, the most frequent site of hypopharyngeal origin.1 Radiation therapy following surgery is the standard therapy. The strategy of combined chemoradiotherapy in the treatment of advanced resectable disease (to avoid mutilating surgery) is known as organ preservation.2 The objective of larynx preservation in patients with pharynx and larynx carcinoma was studied in 3 randomized trials with combined platinum-fluorouracil chemotherapy in a neoadjuvant setting: these regimens were able to preserve the larynx in nearly 23% of patients after 5 years of follow-up, with no significant difference in survival compared with the standard treatment, ie, surgery and postoperative irradiation.3-5 Findings in laboratory and clinical studies suggest that concomitant administration of platinum-based chemotherapy and irradiation seems to be more effective than sequential treatment.6,7 Previous studies have found advantages to using multiple fractions per day for radiation therapy.8,9 However, the standard chemoradiotherapy regimen in these conditions remains to be determined.

This publication has 13 references indexed in Scilit: